AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Financial Results | Lyell Immunopharma 2025 Q1 Revenue USD 0.01 Million Net Loss USD 52.20 Million
ByAinvest
Wednesday, May 14, 2025 2:00 am ET1min read
Lyell Immunopharma(LYEL) posted the Q1 of its 2025 financial results on 5/13/2025, reporting total revenue of USD 0.01 million in the first quarter, up 133.33% from USD 0.00 million year over year, reporting net loss of USD 52.20 million in the first quarter, narrowing 13.96% from USD -60.67 million year over year. The EPS is USD -0.18 in the frist quater, compare with USD -0.24 last period.
[Detailed Data]
| Million USD | Q1 2025 | Q4 2024 | Q3 2024 | Q4 2024 |
|---|---|---|---|---|
| Total Revenue | 0.01 | 0.01 | 0.03 | 0.01 |
| Gross Profit | 0.01 | 0.01 | 0.03 | 0.01 |
| Total Operating Expenses | 53.51 | 196.24 | 44.57 | 196.24 |
| Operating Income | -53.51 | -196.23 | -44.54 | -196.23 |
| Net Income | -52.20 | -191.94 | -44.58 | -191.94 |
| Net Income Attributable to Common Shareholders | -52.20 | -191.94 | -44.58 | -191.94 |
| EPS(USD) | -0.18 | -0.6509 | -0.17 | -0.6509 |
[Company Profile]
Lyell Immunopharma, Inc. was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company expecting to enter pivotal trials in 2025 and advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor T-cell product candidates for patients with hematologic malignancies and solid tumors. The company is pioneering novel approaches designed to generate T cells that drive long-lasting clinical responses. The patient’s living cells are the starting point for the company investigational CAR T-cell therapies, and the company enhance with innovative CAR constructs, technology and manufacturing protocols.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet